Navigation Links
Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
Date:1/31/2013

KANSAS CITY, Kan. and BOSTON, Jan. 31, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has closed on a $12 million Series C financing.  Proceeds will fund the continued expansion of Aratana's pipeline of companion animal therapeutic products.  Existing Aratana investors, as well as new investors, participated in the over-subscribed financing.

"Aratana is on a strong growth trajectory," stated Steven St. Peter , M.D., President and Chief Executive Officer of Aratana Therapeutics.  "As we focus on advancing our current development pipeline toward approval and commercialization, we will use funds from this round to add to our portfolio of animal health products, ensuring Aratana's future growth.  We thank our investors for their support and enthusiasm and together we look forward to continued successful execution from our expert senior development and commercial team."

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit www.aratanatherapeutics.com.

For Investors & Media:
Joshua Drumm , Ph.D. / Andrew Mielach
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
amielach@tiberend.com


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
2. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
3. Aratana to Participate in Leerink Swanns November Management Access Days
4. Aethlon Medical Discloses CEO Interview
5. Wright Therapy Products, Inc. Closes $3 million Financing Round
6. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
7. Edison Pharmaceuticals Closes $20M Series F Financing
8. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
9. Novelos Therapeutics Closes $2 Million Private Placement
10. RxAnte Closes Series A Financing
11. Aethlon Medical Discloses MD Anderson Cancer Center Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):